Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US advisers endorse PCSK9 Praluent, but limited population

This article was originally published in Scrip

Executive Summary

Not wanting to withhold a new type of cholesterol-lowering drug for two years from desperate patients while waiting for cardiovascular outcomes trial (CVOT) data, a panel of experts on 9 June supported Sanofi and Regeneron Pharmaceuticals putting their proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor Praluent (alirocumab) on the US market, despite fears that an FDA approval could mean the large study testing the medicine's ability to prevent heart attacks may be abandoned.

You may also be interested in...



Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha

Labeling for reduction of cardiovascular risk may help a bit with payers, but the "twin problem" of pricing and lack of patient adherence is likely to continue to present hurdles for reimbursement.

Phase III Boost For Esperion But Does It Own Its Destiny?

Esperion will be allowed to enroll patients on high dose statins into the Phase III pivotal trial of its cholesterol lowering drug bempedoic acid, but with competing products ahead in the race, the product faces an uphill battle for market share even if it does garner approval.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Topics

Related Companies

UsernamePublicRestriction

Register

SC028945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel